Acceleron Pharma Inc. (XLRN) CFO Kevin F. Mclaughlin Sells 16,000 Shares
Acceleron Pharma Inc. (NASDAQ:XLRN) CFO Kevin F. Mclaughlin sold 16,000 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $38.41, for a total transaction of $614,560.00. Following the completion of the sale, the chief financial officer now owns 50,810 shares of the company’s stock, valued at approximately $1,951,612.10. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Shares of Acceleron Pharma Inc. (NASDAQ XLRN) traded up 0.50% on Thursday, reaching $39.94. 465,608 shares of the company were exchanged. Acceleron Pharma Inc. has a 12 month low of $23.07 and a 12 month high of $41.69. The company’s 50-day moving average price is $35.47 and its 200 day moving average price is $30.78. The company’s market cap is $1.55 billion.
Acceleron Pharma (NASDAQ:XLRN) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.12). The firm had revenue of $3.10 million for the quarter, compared to analyst estimates of $3.69 million. Acceleron Pharma had a negative net margin of 724.22% and a negative return on equity of 44.67%. The business’s revenue for the quarter was down 3.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.59) EPS. On average, equities research analysts expect that Acceleron Pharma Inc. will post ($2.70) EPS for the current year.
Several equities research analysts have weighed in on the stock. CIBC cut shares of Acceleron Pharma from an “outperform” rating to a “market perform” rating in a research report on Tuesday, June 13th. Royal Bank Of Canada began coverage on shares of Acceleron Pharma in a research report on Thursday. They set a “sector perform” rating for the company. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Acceleron Pharma in a research report on Tuesday, June 13th. Morgan Stanley lowered their price target on shares of Acceleron Pharma from $51.00 to $42.00 and set an “overweight” rating for the company in a research report on Tuesday, June 13th. Finally, Credit Suisse Group reiterated a “buy” rating and set a $46.00 price target on shares of Acceleron Pharma in a research report on Tuesday, July 4th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $42.21.
Large investors have recently added to or reduced their stakes in the business. BNP Paribas Arbitrage SA increased its position in Acceleron Pharma by 969.9% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,627 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 3,288 shares during the period. NJ State Employees Deferred Compensation Plan acquired a new stake in shares of Acceleron Pharma during the 2nd quarter worth approximately $213,000. Bank of Montreal Can acquired a new stake in shares of Acceleron Pharma during the 1st quarter worth approximately $237,000. Parametric Portfolio Associates LLC acquired a new stake in shares of Acceleron Pharma during the 1st quarter worth approximately $241,000. Finally, Tudor Investment Corp ET AL grew its position in shares of Acceleron Pharma by 8.5% during the 1st quarter. Tudor Investment Corp ET AL now owns 9,105 shares of the biopharmaceutical company’s stock worth $241,000 after buying an additional 716 shares during the period. 88.07% of the stock is owned by institutional investors and hedge funds.
About Acceleron Pharma
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.